Financial Performance - The company's operating revenue for Q1 2024 was CNY 308,495,149.50, representing a year-on-year increase of 20.94%[15] - Net profit for the same period was CNY 34,172,999.88, reflecting a growth of 15.16% compared to the previous year[15] - The net profit attributable to shareholders of the listed company was CNY 33,257,419.94, up by 9.26% year-on-year[15] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 31,348,917.48, an increase of 7.06%[15] - Net profit for Q1 2024 reached ¥34.17 million, a significant increase of 15.06% compared to ¥29.67 million in Q1 2023[30] - Basic and diluted earnings per share for Q1 2024 were both ¥0.047, up from ¥0.043 in Q1 2023, reflecting an increase of 9.30%[32] - Operating profit for Q1 2024 was approximately ¥37.56 million, an increase of 5.91% from ¥35.46 million in Q1 2023[30] - The company reported a total profit of approximately ¥37.54 million for Q1 2024, up from ¥35.45 million in Q1 2023, marking a growth of 5.85%[30] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 5,286,184,678.22, a decrease of 2.04% from the end of the previous year[4] - The equity attributable to shareholders of the listed company was CNY 4,744,731,078.85, showing an increase of 0.71% compared to the end of the previous year[4] - The total assets of the company amounted to approximately ¥5.29 billion, a decrease from ¥5.40 billion in the previous period, reflecting a decline of about 2.05%[26] - Total liabilities as of March 31, 2024, amounted to ¥431,386,826.31, down from ¥575,700,678.51 at the end of 2023, a reduction of 25%[44] - The company's total equity increased to ¥4,854,797,851.91 as of March 31, 2024, compared to ¥4,820,624,852.03 at the end of 2023, reflecting a growth of 0.7%[44] - The total current liabilities decreased to ¥382,872,743.91 as of March 31, 2024, from ¥525,543,188.90 at the end of 2023, a decrease of 27.1%[43] Cash Flow - The net cash flow from operating activities was negative CNY 75,537,833.74, a decline of 69.28%[4] - Cash flow from operating activities for Q1 2024 was negative at approximately -¥75.54 million, worsening from -¥44.62 million in Q1 2023[32] - Investment activities resulted in a net cash outflow of approximately -¥322.41 million in Q1 2024, compared to -¥153.04 million in Q1 2023, indicating increased investment expenditures[33] - The company reported a cash and cash equivalents balance of approximately ¥3.02 billion at the end of Q1 2024, down from ¥3.03 billion at the end of Q1 2023[33] - Cash and cash equivalents decreased to ¥3,033,694,706.47 as of March 31, 2024, down from ¥3,437,252,568.45 at the end of 2023, a decline of 11.7%[40] Operational Highlights - The company reported a significant increase of 123.54% in construction in progress due to the factory construction of its subsidiary[7] - The company recognized government subsidies amounting to CNY 2,208,021.28, which are closely related to its normal business operations[4] - Research and development expenses increased to ¥35,189,394.52 in Q1 2024, compared to ¥28,849,435.87 in Q1 2023, marking a rise of 22%[46] - The company recognized a VAT refund of approximately ¥4.54 million, which is expected to be sustainable and included in regular profits[35] - The company plans to continue investing in new product development and market expansion strategies in the upcoming quarters[51] Shareholder Information - The company has a significant shareholder, Midea Group Co., Ltd., holding 45.46% of shares, amounting to 319,579,981 shares[21] - The company has a total of 157,335,122 circulating shares, all of which are RMB ordinary shares[21] - The company has not disclosed any related party relationships among the top shareholders, indicating no known associations or concerted actions[21]
万东医疗(600055) - 2024 Q1 - 季度财报